Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Varicella Zoster (HHV-3) Infections Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Varicella Zoster (HHV-3) Infections Overview | 10 | 1 |
| Pipeline Products for Varicella Zoster (HHV-3) Infections Comparative Analysis | 11 | 1 |
| Varicella Zoster (HHV-3) Infections Therapeutics under Development by Companies | 12 | 2 |
| Varicella Zoster (HHV-3) Infections Therapeutics under Investigation by Universities/Institutes | 14 | 1 |
| Varicella Zoster (HHV-3) Infections Pipeline Products Glance | 15 | 4 |
| Late Stage Products | 15 | 1 |
| Clinical Stage Products | 16 | 1 |
| Early Stage Products | 17 | 1 |
| Unknown Stage Products | 18 | 1 |
| Varicella Zoster (HHV-3) Infections Products under Development by Companies | 19 | 1 |
| Varicella Zoster (HHV-3) Infections Products under Investigation by Universities/Institutes | 20 | 1 |
| Varicella Zoster (HHV-3) Infections Companies Involved in Therapeutics Development | 21 | 19 |
| Astellas Pharma Inc. | 21 | 1 |
| Beijing Minhai Biotechnology Co., Ltd | 22 | 1 |
| Beijing Tiantan Biological Products Co., Ltd. | 23 | 1 |
| ContraVir Pharmaceuticals, Inc. | 24 | 1 |
| Epiphany Biosciences, Inc. | 25 | 1 |
| Foamix Pharmaceuticals Ltd. | 26 | 1 |
| GeneOne Life Science, Inc. | 27 | 1 |
| GlaxoSmithKline Plc | 28 | 1 |
| Green Cross Corporation | 29 | 1 |
| Merck &Co., Inc. | 30 | 1 |
| N &N Pharmaceuticals Inc. | 31 | 1 |
| NAL Pharmaceuticals Ltd. | 32 | 1 |
| NanoViricides, Inc. | 33 | 1 |
| ReceptoPharm, Inc. | 34 | 1 |
| Sinovac Biotech Ltd. | 35 | 1 |
| SK Chemicals Co., Ltd. | 36 | 1 |
| TSRL, Inc. | 37 | 1 |
| XBiotech Inc | 38 | 1 |
| Zydus Cadila Healthcare Limited | 39 | 1 |
| Varicella Zoster (HHV-3) Infections Therapeutics Assessment | 40 | 10 |
| Assessment by Monotherapy Products | 40 | 1 |
| Assessment by Combination Products | 41 | 1 |
| Assessment by Target | 42 | 2 |
| Assessment by Mechanism of Action | 44 | 2 |
| Assessment by Route of Administration | 46 | 2 |
| Assessment by Molecule Type | 48 | 2 |
| Drug Profiles | 50 | 33 |
| (measles + mumps + rubella + varicella) vaccine Drug Profile | 50 | 1 |
| (measles + rubella + varicella) vaccine Drug Profile | 51 | 1 |
| acyclovir Drug Profile | 52 | 1 |
| amenamevir Drug Profile | 53 | 1 |
| chickenpox vaccine Drug Profile | 54 | 1 |
| FV-100 Drug Profile | 55 | 4 |
| GLS-5100 Drug Profile | 59 | 1 |
| GSK-1437173A Drug Profile | 60 | 3 |
| herpes zoster vaccine Drug Profile | 63 | 1 |
| HHV-3 vaccine Drug Profile | 64 | 1 |
| measles + mumps + rubella + varicella vaccine Drug Profile | 65 | 1 |
| MG-1111 Drug Profile | 66 | 1 |
| Monoclonal Antibody for Shingles Drug Profile | 67 | 1 |
| NAL-3221 Drug Profile | 68 | 1 |
| NAL-3223 Drug Profile | 69 | 1 |
| NBP-608 Drug Profile | 70 | 1 |
| NN-001 Drug Profile | 71 | 1 |
| RKP-00156 Drug Profile | 72 | 1 |
| RPI-78M Drug Profile | 73 | 2 |
| sattabacin Drug Profile | 75 | 1 |
| Small Molecule for Shingles Drug Profile | 76 | 1 |
| TSR-087 Drug Profile | 77 | 1 |
| V-212 Drug Profile | 78 | 2 |
| valomaciclovir stearate Drug Profile | 80 | 2 |
| varicella zoster vaccine Drug Profile | 82 | 1 |
| Varicella Zoster (HHV-3) Infections Dormant Projects | 83 | 1 |
| Varicella Zoster (HHV-3) Infections Discontinued Products | 84 | 1 |
| Varicella Zoster (HHV-3) Infections Product Development Milestones | 85 | 11 |
| Featured News &Press Releases | 85 | 1 |
| Sep 14, 2016: GSKs candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM | 85 | 1 |
| Jun 16, 2016: ContraVir Pharmaceuticals Expands Patient Enrollment Criteria for Ongoing Phase 3 Clinical Study of FV-100 for Treating Shingles | 86 | 1 |
| Apr 20, 2016: N&N Pharmaceuticals Commences Clinical Trials on its Novel Antiviral Drug | 87 | 1 |
| Mar 03, 2016: ContraVir Pharmaceuticals Reports Positive Results Confirming the Safety of its Shingles Candidate FV-100 in a Drug-Drug Interaction Study | 87 | 1 |
| Oct 27, 2015: GSK s candidate shingles vaccine demonstrates 90% efficacy against shingles in people 70 years of age and over | 88 | 1 |
| Oct 26, 2015: Sinovac Receives Clinical Trial Approval for Varicella Vaccine Candidate | 89 | 1 |
| Sep 08, 2015: Clinical trial for Cardiff s shingles treatment | 89 | 1 |
| Aug 03, 2015: ContraVir Pharmaceuticals Enrolls First Patient in Pivotal Phase 3 Study of FV-100 for Treatment of Shingles and Shingles-Associated Pain | 90 | 1 |
| Jun 09, 2015: ContraVir Pharmaceuticals Selects ImageIQ as Imaging CRO for Phase III Clinical Trial | 91 | 1 |
| Apr 28, 2015: GSK candidate vaccine for the prevention of shingles demonstrates overall efficacy of 97.2% which does not diminish in the age groups studied | 91 | 1 |
| Mar 09, 2015: ContraVir Pharmaceuticals to Initiate Pivotal Phase 3 Study of FV-100 for Prevention of Shingles-Associated PHN | 92 | 1 |
| Dec 18, 2014: Pivotal phase III study of GSK shingles candidate vaccine meets its primary endpoint | 93 | 1 |
| Dec 18, 2014: Positive Outcome of Phase 3 Study of GSK Shingles Vaccine Containing Agenus Adjuvant | 94 | 1 |
| Dec 09, 2014: ContraVir Pharmaceuticals Initiates Pharmacokinetic Study of Lead Antiviral FV-100 for Treating Shingles | 94 | 1 |
| Oct 16, 2014: ContraVir Pharmaceuticals Selects Pharmaceutical Product Development to Manage Phase 2b Study of Lead Antiviral FV-100 for Treating Shingles | 95 | 1 |
| Appendix | 96 | 2 |
| Methodology | 96 | 1 |
| Coverage | 96 | 1 |
| Secondary Research | 96 | 1 |
| Primary Research | 96 | 1 |
| Expert Panel Validation | 96 | 1 |
| Contact Us | 96 | 1 |
| Disclaimer | 97 | 1 |
